Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. - Wikidata - awgldk - TriplyDB

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34655579

about

The Obesity Paradox in Cancer: a Review Adjuvant systemic therapy in older women with breast cancer Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies Main controversies in breast cancer Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers Breast cancer associated with neurofibromatosis type 1: a case series and review of the literature The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research N-3 Polyunsaturated Fatty Acids of Marine Origin and Multifocality in Human Breast Cancer Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.The burden of breast cancer from China to Italy Female breast cancer in Europe: statistics, diagnosis and treatment modalities.Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases Relationship of clinical and pathologic nodal staging in locally advanced breast cancer: current controversies in daily practice?Health services utilisation in breast cancer survivors in Taiwan.Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report Imaging surveillance of patients with breast cancer after primary treatment: current recommendations Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.Dosimetric comparison of the simultaneous integrated boost in whole-breast irradiation after breast-conserving surgery: IMRT, IMRT plus an electron boost and VMAT.A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer.Optimal systemic therapy for early breast cancer in women: a clinical practice guideline uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Rare breast malignancies and review of literature: A single centres experience.Nipple-sparing mastectomy in breast cancer patients: The role of adjuvant radiotherapy (Review).Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study.The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials.Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.Rapid intraoperative visualization of breast lesions with γ-glutamyl hydroxymethyl rhodamine green Fine needle aspiration cytology of lymph nodes in breast cancer follow-up is a feasible alternative to watchful waiting and to histology.Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.Early-stage breast cancer is not associated with the risk of marital dissolution in a large prospective study of women.

P2860

Q26740435-35A54E03-BE0A-47F9-9A33-465FBD70DF2D Q26741523-ED2B6BDD-E920-4664-85E7-8FCCC428FC2D Q26748850-2D77C58A-8A37-4DCD-AB79-66C0CFD7AF02 Q26766045-618F936C-CD42-4641-9B02-9E9E296B28E2 Q26773012-1692770E-E6F2-4AD6-9D3A-3D173C2966EE Q26776288-D8DFDF18-E8AC-4AA5-A21F-EC461A1849EE Q26782584-51197F47-709C-42C1-A190-9A6009FBB375 Q26783705-69F0F718-E936-488D-96AA-8A436DA20156 Q27026673-B55A46A4-F56E-462E-A920-B26E945A4D0E Q28076777-71A0322E-5801-438F-9074-507589C4D11F Q28083633-B79C06B9-6CAF-4B9A-9550-748B83D59ADE Q28084508-A8A8CB83-2E5D-40B4-90D0-42901CAC4722 Q28085160-E986BC2A-B245-4F2E-B3A2-885CFE618523 Q28258209-DCAF732B-00E0-4B24-AD6D-E73628ED5FE1 Q28388726-B9B6F205-3AC0-48F2-BF38-38549F60EAE8 Q28552899-04AC31CF-4D96-4262-AC45-A670B01A3A49 Q30490708-9EA3BFDD-9FA0-44F8-AB76-19167A20654C Q33814691-292DA360-5275-43DD-BA3C-04720ECCF12F Q33814729-30293AD3-FA23-4DF1-BE14-6F6EB27146EF Q33967497-2DFCDE2E-2C02-4B21-B6E6-E6547C3D39CD Q34212998-EACBC46E-EC82-42CE-81F1-2A2F452355EE Q34684144-1853C353-20D7-493D-9B7E-5BEC801807F7 Q35101412-515ABBE0-58A9-415B-A81D-CDD32E10C5DB Q35140150-6FD737BE-E756-4F4A-BA03-5D9603CDFFDA Q35143022-65E69C0E-FAC4-46E6-953D-055CC551616E Q35171432-BE9E32F3-D99A-49DA-A6FD-92AA6C8A74E0 Q35187878-B5B0EDB0-688F-46AB-B0E8-FB6539DB29C0 Q35198325-01AD5A61-87F8-4490-819A-19B76CA84129 Q35239634-E543DE35-90A1-4EF1-A4EA-49B802A6DF70 Q35580701-ADF53F52-8C8A-4D2F-819B-2BF0B9B647BB Q35657658-9EFC8125-B5FA-4693-A14C-3121252ACA52 Q35681465-D02101B4-7541-4BF0-BE81-127C624C5F10 Q35692692-A08095F9-90DE-4D52-8DFF-BACFF459EA3E Q35763286-33D9C8CE-C8F1-417A-9143-D160323D6AB5 Q35820496-182F169B-278F-4BDA-BF79-7E60661E7696 Q35826503-BCA7768D-0F8C-48F8-A3C5-138206417706 Q35844556-8E6435A4-47DE-409B-9A85-A6966CFD8D35 Q35859450-74729B45-773D-41F8-9012-D6A3EFE9C745 Q35881343-7170145F-DAD8-4FBC-9D46-ADDEF598A86B Q35909598-95C4AA40-25E7-4708-9E69-C856865A72AA

P2860

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34655579

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@ast

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@en

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@nl

type

label

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@ast

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@en

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@nl

prefLabel

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@ast

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@en

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@nl

P1433

Q34655579-019230B5-CE83-463B-9B38-3AB416DD72F8

P1476

Q34655579-7AEE9AA8-C863-4655-BF26-E5ADE10D1D05

P2093

Q34655579-08AE2E56-438B-4ED4-AAD8-59FE5C809827

Q34655579-840760C7-82A0-404D-BB5C-D8E834045F2D

Q34655579-8D37EC56-F76B-4467-9E9E-A8BD87ED95C1

Q34655579-B58E4FD8-6F07-490C-B4ED-3B4BAF9B6D14

Q34655579-E3A40CC6-E2E0-48E0-8DA8-40890F2B57C0

Q34655579-F4F4C7CF-4443-4A1D-90CE-BB51F496B467

Q34655579-F64579F1-B8C8-41AF-961F-AFDF21886AA7

P2860

Q34655579-02D38BD2-5186-4C46-AC74-A8B68E64F114

Q34655579-04D537D0-63C1-4E38-94A3-50EFE7DBBE7F

Q34655579-05870C9A-3A5A-41B2-8963-43AB2F9BD62F

Q34655579-074AA11C-E1C3-41A3-98DB-25C6E86E0385

Q34655579-07802338-8F73-4875-9D42-5E0BC405BF49

Q34655579-0BF24F71-6310-4681-9C51-3BC9D3D48E16

Q34655579-106FFF6B-A136-44CD-9DDE-B6335661946A

Q34655579-137EBD57-C555-42BA-9A21-C5572AC30083

Q34655579-16F518C6-1283-4950-8185-D50E57471BB1

Q34655579-1B225596-6F22-4548-914E-462862E11BDD

P304

Q34655579-565CCE55-B6BF-414B-8420-51C94E5BF4D0

P31

Q34655579-A3CD9ACE-CCB2-4528-897E-0A1D8FDC3333

P356

Q34655579-3151079D-A894-466D-8451-5E7B96E9FDA5

P478

Q34655579-2D4CD004-449F-475E-9C6D-2452C386D166

P50

Q34655579-250BC46C-1509-4085-BBC0-3BF87F4ED366

P577

Q34655579-C80B79D6-C897-4F38-B847-33D66CD792CA

P5875

Q34655579-BFF055A2-48B6-451A-A268-9EE7890CB14E

P698

Q34655579-EC03264E-8080-4641-B091-3F0F3A07EDFE

P356

P1433

Annals of Oncology

P1476

Primary breast cancer: ESMO Cl ...... osis, treatment and follow-up.

@en

P2093

A Thompson

http://www.w3.org/2001/XMLSchema#string

E Senkus

http://www.w3.org/2001/XMLSchema#string

ESMO Guidelines Working Group

http://www.w3.org/2001/XMLSchema#string

F Cardoso

http://www.w3.org/2001/XMLSchema#string

P Poortmans

http://www.w3.org/2001/XMLSchema#string

S Kyriakides

http://www.w3.org/2001/XMLSchema#string

S Zackrisson

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

P304

vi7-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDT284

http://www.w3.org/2001/XMLSchema#string

P478

24 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P50

Frédérique Penault-Llorca

P577

2013-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261319542

http://www.w3.org/2001/XMLSchema#string

P698

23970019

http://www.w3.org/2001/XMLSchema#string